Generic placeholder image

Current Cancer Drug Targets

Editor-in-Chief

ISSN (Print): 1568-0096
ISSN (Online): 1873-5576

Small Molecule Inhibitors of Multidrug Resistance Gene (MDR1) Expression: Preclinical Evaluation and Mechanisms of Action

Author(s): Sofia A. Santos and Alexandra Paulo

Volume 13, Issue 8, 2013

Page: [814 - 828] Pages: 15

DOI: 10.2174/15680096113139990082

Price: $65

Abstract

The resistance of tumors to a number of structurally and functionally unrelated chemotherapeutic drugs has been a major obstacle for successful cancer chemotherapy. An important mechanism leading to multidrug resistance (MDR) is the overexpression of the 170 kDa P-glycoprotein (P-gp), which is a member of the ATP-binding cassette (ABC) superfamily of membrane transporters, encoded by the MDR1 gene. Aiming to overcome MDR and due to the clinical failure of P-gp inhibitors, downregulation of MDR1 expression by small molecules has been studied as a possible cancer adjuvant chemotherapy. Here we review the current knowledge on MDR1 gene expression downregulation by small molecules and the mechanisms underlying those effects observed in cancer cell lines, in an attempt to identify targets for future therapeutic interventions.

Keywords: Cancer, downregulators, gene expression regulation, MDR1 gene, multidrug resistance, P-glycoprotein, transcription regulation.


Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy